{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T12:32:38Z","timestamp":1762432358058,"version":"3.41.2"},"reference-count":46,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,4,17]],"date-time":"2023-04-17T00:00:00Z","timestamp":1681689600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100005150","name":"Chinese Academy of Medical Sciences","doi-asserted-by":"publisher","award":["CIFMS 2021-I2M-1-014"],"award-info":[{"award-number":["CIFMS 2021-I2M-1-014"]}],"id":[{"id":"10.13039\/501100005150","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006190","name":"Research and Development","doi-asserted-by":"publisher","award":["2018YFE0207300"],"award-info":[{"award-number":["2018YFE0207300"]}],"id":[{"id":"10.13039\/100006190","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004826","name":"Beijing Natural Science Foundation","doi-asserted-by":"publisher","award":["M23008"],"award-info":[{"award-number":["M23008"]}],"id":[{"id":"10.13039\/501100004826","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Public Health"],"abstract":"<jats:sec><jats:title>Introduction<\/jats:title><jats:p>Breast cancer is the most prevalent malignancy in patients with coronavirus disease 2019 (COVID-19). However, vaccination data of this population are limited.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>A cross-sectional study of COVID-19 vaccination was conducted in China. Multivariate logistic regression models were used to assess factors associated with COVID-19 vaccination status.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Of 2,904 participants, 50.2% were vaccinated with acceptable side effects. Most of the participants received inactivated virus vaccines. The most common reason for vaccination was \u201cfear of infection\u201d (56.2%) and \u201cworkplace\/government requirement\u201d (33.1%). While the most common reason for nonvaccination was \u201cworry that vaccines cause breast cancer progression or interfere with treatment\u201d (72.9%) and \u201chave concerns about side effects or safety\u201d (39.6%). Patients who were employed (odds ratio, OR\u2009=\u20091.783, <jats:italic>p<\/jats:italic>\u2009=\u20090.015), had stage I disease at diagnosis (OR\u2009=\u20092.008, <jats:italic>p<\/jats:italic>\u2009=\u20090.019), thought vaccines could provide protection (OR\u2009=\u20091.774, <jats:italic>p<\/jats:italic>\u2009=\u20090.007), thought COVID-19 vaccines were safe, very safe, not safe, and very unsafe (OR\u2009=\u20092.074, <jats:italic>p<\/jats:italic>\u2009&amp;lt;\u20090.001; OR\u2009=\u20094.251, <jats:italic>p<\/jats:italic>\u2009&amp;lt;\u20090.001; OR\u2009=\u20092.075, <jats:italic>p<\/jats:italic>\u2009=\u20090.011; OR\u2009=\u20095.609, <jats:italic>p<\/jats:italic>\u2009=\u20090.003, respectively) were more likely to receive vaccination. Patients who were 1\u20133\u2009years, 3\u20135\u2009years, and more than 5\u2009years after surgery (OR\u2009=\u20090.277, <jats:italic>p<\/jats:italic>\u2009&amp;lt;\u20090.001; OR\u2009=\u20090.277, <jats:italic>p<\/jats:italic>\u2009&amp;lt;\u20090.001, OR\u2009=\u20090.282, <jats:italic>p<\/jats:italic>\u2009&amp;lt;\u20090.001, respectively), had a history of food or drug allergies (OR\u2009=\u20090.579, <jats:italic>p<\/jats:italic>\u2009=\u20090.001), had recently undergone endocrine therapy (OR\u2009=\u20090.531, <jats:italic>p<\/jats:italic>\u2009&amp;lt;\u20090.001) were less likely to receive vaccination.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>COVID-19 vaccination gap exists in breast cancer survivors, which could be filled by raising awareness and increasing confidence in vaccine safety during cancer treatment, particularly for the unemployed individuals.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fpubh.2023.1119163","type":"journal-article","created":{"date-parts":[[2023,4,17]],"date-time":"2023-04-17T06:00:53Z","timestamp":1681711253000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":3,"title":["COVID-19 vaccination status, side effects, and perceptions among breast cancer survivors: a cross-sectional study in China"],"prefix":"10.3389","volume":"11","author":[{"given":"Yali","family":"Xu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Linrong","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaomeng","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haolong","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu","family":"Song","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yongmei","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chang","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haoting","family":"Zhan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhe","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xinxin","family":"Feng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yingjiao","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guanmo","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yang","family":"Qu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuechong","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yongzhe","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qiang","family":"Sun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2023,4,17]]},"reference":[{"year":"","key":"ref1"},{"year":"","key":"ref2"},{"year":"","key":"ref3"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"1907","DOI":"10.1016\/S0140-6736(20)31187-9","article-title":"Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study","volume":"395","author":"Kuderer","year":"2020","journal-title":"Lancet"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"2000547","DOI":"10.1183\/13993003.00547-2020","article-title":"Comorbidity and its impact on 1590 patients with COVID-19 in China: a nationwide analysis","volume":"55","author":"Guan","year":"2020","journal-title":"Eur Respir J"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.1001\/jama.2020.2648","article-title":"Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72 314 cases from the Chinese Center for Disease Control and Prevention","volume":"323","author":"Wu","year":"2020","journal-title":"JAMA"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1158\/2159-8290.CD-20-0516","article-title":"Case fatality rate of cancer patients with COVID-19 in a New York hospital system","volume":"10","author":"Mehta","year":"2020","journal-title":"Cancer Discov"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"4144","DOI":"10.1002\/jmv.27828","article-title":"Immunogenicity of COVID-19 vaccines in patients with diverse health conditions: a comprehensive systematic review","volume":"94","author":"Cho","year":"2022","journal-title":"J Med Virol"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1016\/S1470-2045(21)00213-8","article-title":"Safety and immunogenicity of one versus two doses of the COVID-19 vaccine BNT162b2 for patients with cancer: interim analysis of a prospective observational study","volume":"22","author":"Monin","year":"2021","journal-title":"Lancet Oncol"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1001\/jamaoncol.2021.7777","article-title":"SARS-CoV-2 antibody response to 2 or 3 doses of the BNT162b2 vaccine in patients treated with anticancer agents","volume":"8","author":"Fenioux","year":"2022","journal-title":"JAMA Oncol"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"4621","DOI":"10.3390\/cancers13184621","article-title":"Responses to SARS-CoV-2 vaccination in patients with cancer (ReCOVer study): a prospective cohort study of the Hellenic cooperative oncology group","volume":"13","author":"Linardou","year":"2021","journal-title":"Cancers (Basel)"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"524","DOI":"10.3322\/caac.21754","volume":"72","author":"Giaquinto","year":"2022","journal-title":"CA A Cancer J Clinicians"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21590","article-title":"Cancer statistics, 2020","volume":"70","author":"Siegel","year":"2020","journal-title":"CA Cancer J Clin"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"JCO2201667","DOI":"10.1200\/JCO.22.01667","article-title":"Pandemic phase-adjusted analysis of COVID-19 outcomes reveals reduced intrinsic vulnerability and substantial vaccine protection from severe acute respiratory syndrome coronavirus 2 in patients with breast cancer","author":"Tagliamento","year":"2023","journal-title":"J Clin Oncol"},{"year":"2022","key":"ref15"},{"year":"2022","key":"ref16"},{"key":"ref17","first-page":"954","article-title":"Diagnosis and treatment guidelines for breast cancer working group. Guideline and standard for the diagnosis and treatment of breast cancer by Chinese anti-cancer association","volume-title":"Cancer Communications","year":"2021"},{"volume-title":"R: A Language and Environment for Statistical Computing","year":"2019","key":"ref18"},{"year":"","key":"ref19"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"e210","DOI":"10.1016\/S2468-2667(21)00012-8","article-title":"COVID-19 vaccine hesitancy in a representative working-age population in France: a survey experiment based on vaccine characteristics","volume":"6","author":"Schwarzinger","year":"2021","journal-title":"Lancet Public Health"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"101845","DOI":"10.1016\/j.pmedr.2022.101845","article-title":"Vaccine hesitancy and COVID-19 immunization among rural young adults","volume":"28","author":"Mann","year":"2022","journal-title":"Prev Med Rep"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"4161","DOI":"10.1016\/j.vaccine.2015.04.036","article-title":"Vaccine hesitancy: definition, scope and determinants","volume":"33","author":"NE","year":"2015","journal-title":"Vaccine"},{"year":"2022","key":"ref23"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"1014942","DOI":"10.3389\/fpubh.2022.1014942","article-title":"Investigation on the hesitancy of COVID-19 vaccination among liver transplant recipients: a cross-sectional study in China","volume":"10","author":"Pan","year":"2022","journal-title":"Front Public Health"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1186\/s12902-022-01201-5","article-title":"The COVID-19 vaccination hesitancy among Chinese individuals with diabetes and the impact on glycemic control of vaccination: a questionnaire study","volume":"22","author":"Lu","year":"2022","journal-title":"BMC Endocr Disord"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1186\/s12879-022-07452-w","article-title":"Acceptance of COVID-19 vaccination and influencing factors among people living with HIV in Guangxi, China: a cross-sectional survey","volume":"22","author":"Su","year":"2022","journal-title":"BMC Infect Dis"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"00034","DOI":"10.1016\/j.jinf.2023.01.030","article-title":"Acceptance, safety and immunogenicity of a booster dose of inactivated SARS-CoV-2 vaccine in adults with tuberculosis","author":"Zhan","year":"2023","journal-title":"J Infect"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"1286","DOI":"10.3390\/vaccines9111286","article-title":"Willingness to receive the booster COVID-19 vaccine dose in Poland","volume":"9","author":"Rzymski","year":"2021","journal-title":"Vaccine"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1186\/s41182-023-00509-9","article-title":"Acceptance and hesitancy to receive COVID-19 vaccine among university students in Egypt: a nationwide survey","volume":"51","author":"Tharwat","year":"2023","journal-title":"Trop Med Health"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1016\/S0140-6736(21)01429-X","article-title":"Efficacy and safety of an inactivated whole-virion SARS-CoV-2 vaccine (CoronaVac): interim results of a double-blind, randomised, placebo-controlled, phase 3 trial in Turkey","volume":"398","author":"Tanriover","year":"2021","journal-title":"Lancet"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/S1473-3099(20)30831-8","article-title":"Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBIBP-CorV: a randomised, double-blind, placebo-controlled, phase 1\/2 trial","volume":"21","author":"Xia","year":"2021","journal-title":"Lancet Infect Dis"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"3573","DOI":"10.3390\/cancers13143573","article-title":"COVID-19 vaccine safety in cancer patients: a single Centre experience","volume":"13","author":"So","year":"2021","journal-title":"Cancers"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1093\/jnci\/djab174","article-title":"Immunogenicity and safety of the BNT162b2 mRNA COVID-19 vaccine among actively treated cancer patients","volume":"114","author":"Ligumsky","year":"2022","journal-title":"J Natl Cancer Inst"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"798975","DOI":"10.3389\/fendo.2022.798975","article-title":"A cohort study on the immunogenicity and safety of the inactivated SARS-CoV-2 vaccine (BBIBP-CorV) in patients with breast cancer; does trastuzumab interfere with the outcome?","volume":"13","author":"Joudi","year":"2022","journal-title":"Front Endocrinol (Lausanne)"},{"key":"ref35","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.ejca.2021.09.033","article-title":"Regional lymphadenopathy following COVID-19 vaccination: literature review and considerations for patient management in breast cancer care","volume":"159","author":"Garreffa","year":"2021","journal-title":"Eur J Cancer"},{"key":"ref36","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1001\/jama.2021.8565","article-title":"Effect of 2 inactivated SARS-CoV-2 vaccines on symptomatic COVID-19 infection in adults: a randomized clinical trial","volume":"326","author":"al Kaabi","year":"2021","journal-title":"JAMA"},{"key":"ref37","doi-asserted-by":"publisher","first-page":"918896","DOI":"10.3389\/fimmu.2022.918896","article-title":"Immunogenicity, effectiveness, and safety of inactivated virus (CoronaVac) vaccine in a two-dose primary protocol and BNT162b2 heterologous booster in Brazil (Immunita-001): a one year period follow up phase 4 study","volume":"13","author":"Grenfell","year":"2022","journal-title":"Front Immunol"},{"key":"ref38","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.1097\/CM9.0000000000001573","article-title":"Immunogenicity and safety of a severe acute respiratory syndrome coronavirus 2 inactivated vaccine in healthy adults: randomized, double-blind, and placebo-controlled phase 1 and phase 2 clinical trials","volume":"134","author":"Pan","year":"2021","journal-title":"Chin Med J"},{"key":"ref39","doi-asserted-by":"publisher","first-page":"2","DOI":"10.21037\/tbcr-21-31","article-title":"Chinese expert consensus on coronavirus disease 2019 vaccination for breast cancer patients","volume":"34","author":"Nie","year":"2021","journal-title":"Trans Breast Cancer Res"},{"key":"ref40","doi-asserted-by":"publisher","first-page":"741204","DOI":"10.3389\/fmed.2021.741204","article-title":"Prevalence and impact factors of COVID-19 vaccination hesitancy among breast cancer survivors: a Multicenter cross-sectional study in China","volume":"8","author":"Peng","year":"2021","journal-title":"Front Med (Lausanne)"},{"key":"ref41","doi-asserted-by":"publisher","first-page":"1358","DOI":"10.3390\/vaccines9111358","article-title":"COVID-19 vaccine hesitancy and attitude toward booster doses among US healthcare workers","volume":"9","author":"Pal","year":"2021","journal-title":"Vaccine"},{"key":"ref42","doi-asserted-by":"publisher","first-page":"1028","DOI":"10.1016\/j.ccell.2021.06.014","article-title":"Highly variable SARS-CoV-2 spike antibody responses to two doses of COVID-19 RNA vaccination in patients with multiple myeloma","volume":"39","author":"van Oekelen","year":"2021","journal-title":"Cancer Cell"},{"key":"ref43","doi-asserted-by":"publisher","first-page":"3057","DOI":"10.1200\/JCO.21.02257","article-title":"Determinants of neutralizing antibody response after SARS CoV-2 vaccination in patients with myeloma","volume":"40","author":"Nooka","year":"2022","journal-title":"J Clin Oncol"},{"key":"ref44","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1186\/s40249-021-00909-1","article-title":"COVID-19 vaccination program in the mainland of China: a subnational descriptive analysis on target population size and current progress","volume":"10","author":"Zheng","year":"2021","journal-title":"Infect Dis Poverty"},{"year":"","key":"ref45"},{"year":"2021","key":"ref46"}],"container-title":["Frontiers in Public Health"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpubh.2023.1119163\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,17]],"date-time":"2023-04-17T06:00:56Z","timestamp":1681711256000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpubh.2023.1119163\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,17]]},"references-count":46,"alternative-id":["10.3389\/fpubh.2023.1119163"],"URL":"https:\/\/doi.org\/10.3389\/fpubh.2023.1119163","relation":{},"ISSN":["2296-2565"],"issn-type":[{"type":"electronic","value":"2296-2565"}],"subject":[],"published":{"date-parts":[[2023,4,17]]},"article-number":"1119163"}}